Susan Greenbloom
Woodbridge, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: June 30, 2022
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Journal: Lancet (London, England)
Published: November 16, 2021
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Journal: Hepatology (Baltimore, Md.)
Published: September 09, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1.
Journal: Hepatology (Baltimore, Md.)
Published: September 28, 2018
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: July 17, 2018
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: November 23, 2016
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
Journal: Journal of hepatology
Published: April 15, 2015
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.
Journal: Journal of hepatology
Published: January 20, 2014
Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.
Journal: Canadian journal of gastroenterology & hepatology
Published: November 12, 2013
Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.
Journal: Journal of hepatology
Published: March 12, 2013
Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3.
Journal: Alimentary pharmacology & therapeutics
Published: November 05, 2011
Showing 1-11 of 11
Last Updated: 09/26/2026